Q1 EPS Estimate for Theravance Biopharma Lowered by Analyst

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Equities researchers at Zacks Research cut their Q1 2025 earnings estimates for Theravance Biopharma in a research note issued to investors on Wednesday, March 19th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will earn ($0.43) per share for the quarter, down from their previous estimate of ($0.36). The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.09) per share. Zacks Research also issued estimates for Theravance Biopharma’s Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.29) EPS, Q1 2026 earnings at ($0.50) EPS, Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at $0.19 EPS, FY2026 earnings at ($1.13) EPS and FY2027 earnings at ($0.96) EPS.

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Theravance Biopharma in a research report on Tuesday, February 25th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $13.75.

Theravance Biopharma Stock Up 0.3 %

TBPH opened at $9.39 on Monday. The business’s fifty day simple moving average is $9.32 and its 200 day simple moving average is $9.06. Theravance Biopharma has a 52 week low of $7.44 and a 52 week high of $10.90. The stock has a market cap of $464.53 million, a PE ratio of -9.30 and a beta of 0.15.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.26). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. The company had revenue of $18.75 million during the quarter, compared to the consensus estimate of $29.90 million.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 309,565 shares in the company, valued at $2,786,085. This trade represents a 1.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Invesco Ltd. boosted its position in shares of Theravance Biopharma by 3.5% during the fourth quarter. Invesco Ltd. now owns 46,050 shares of the biopharmaceutical company’s stock valued at $433,000 after purchasing an additional 1,576 shares in the last quarter. Jane Street Group LLC lifted its position in Theravance Biopharma by 1.1% during the third quarter. Jane Street Group LLC now owns 144,575 shares of the biopharmaceutical company’s stock valued at $1,165,000 after buying an additional 1,640 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Theravance Biopharma by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 293,936 shares of the biopharmaceutical company’s stock valued at $2,766,000 after buying an additional 2,060 shares in the last quarter. Aquatic Capital Management LLC purchased a new stake in shares of Theravance Biopharma in the 4th quarter worth about $25,000. Finally, SG Americas Securities LLC increased its stake in shares of Theravance Biopharma by 21.1% in the 4th quarter. SG Americas Securities LLC now owns 19,202 shares of the biopharmaceutical company’s stock worth $181,000 after acquiring an additional 3,349 shares in the last quarter. Institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.